Journal article
Rituximab utilization for approved and off‐label nononcology indications and patients’ experiences with the Patient Alert Card
Abstract
This study used retrospective chart review and survey data to evaluate: (1) off-label use of rituximab (MabThera®/Rituxan®) in autoimmune conditions and (2) patients' receipt and knowledge of the Patient Alert Card (PAC), a risk minimization measure for progressive multifocal leukoencephalopathy (PML) and serious infections. Anonymized patient data were collected from infusion centers in Europe from December 2015 to July 2017. Adults receiving …
Authors
Sarsour K; Beckley‐Kartey S; Melega S; Odueyungbo A; Kirchner P; Khalife N; Bangs J
Journal
Pharmacology Research & Perspectives, Vol. 8, No. 1,
Publisher
Wiley
Publication Date
February 2020
DOI
10.1002/prp2.555
ISSN
2052-1707